

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	To be assigned
	<b>Filing Date</b>	March 8, 2004
	<b>First Named Inventor</b>	Calabresi
	<b>Group Art Unit</b>	1616
	<b>Examiner Name</b>	To be assigned
	<b>Attorney Docket Number</b>	21486-031CON2

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
ME	A1	3,423,408	01/21/69	Pfirmann	260	243	
	A2	3,963,706	06/15/76	Pfirmann	260	239.9	
	A3	4,096,241	06/20/78	Geistlich et al.	424	54	
	A4	4,107,305	08/15/78	Pfirmann	424	246	
	A5	4,226,858	10/07/80	Pfirmann	424	125	
	A6	4,337,251	06/29/82	Pfirmann	424	246	
	A7	4,587,268	05/06/86	Pfirmann	514	774	
	A8	4,604,391	08/05/86	Pfirmann	514	222	
	A9	4,626,536	12/02/86	Pfirmann	514	222	
	A10	4,772,468	09/20/88	Pfirmann	424	128	
	A11	5,210,083	05/11/93	Pfirmann	514	222.5	
	A12	5,573,771	11/12/96	Geistlich et al.	424	422	
	A13	5,593,665	01/14/97	Pfirmann et al.	424	85.1	
	A14	5,819,748	10/13/98	Pfirmann	128	898	
	A15	5,972,933	10/26/99	Pfirmann	514	222.5	
	A16	5,954,687	09/21/99	Baudino	604	48	
	A17	5,976,822	11/2/99	Landrum et al.	435	23	
	A18	6,011,030	01/04/00	Pfirmann	514	222.2	
	A19	6,080,397	06/27/00	Pfirmann et al.	424	78.08	
ME	A20	6,117,868	09/12/00	Pfirmann	514	222.5	
ME	A21	6,303,596	10/16/01	Morrissey et al.	514	222.5	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
ME	B1	WO	91/13628	Pfirmann et al.	09/19/91		
	B2	WO	92/00743	ED Geistlich Sohne AG fur Chemische Industrie	01/23/92		
	B3	WO	98/52572	Oklahoma Medical Research Foundation	11/26/98		
	B4	WO	99/06114	ED Geistlich Sohne AG fur Chemische Industrie	02/11/99		
	B5	WO	99/34805	ED Geistlich Sohne AG fur Chemische Industrie	07/15/99		
	B6	EPO	0253662	ED Geistlich Sohne AG fur Chemische Industrie	01/20/88		
ME	B7	EPO	1066830	ED Geistlich Sohne AG fur Chemische Industrie	01/10/01		

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
ME	B8	WO	90/06138	Holmes et al	05/14/90	
ME	B9	WO	94/03174	Holmes et al	02/17/94	
OTHER NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
ME	C1	Blenkharn et al. (1987) "The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics," <i>Surg. Res. Commun.</i> , 2:149-155				
	C2	Browne M.K. et al. (1985) "Studies on the Antiendotoxin Properties of Taurolin in Animals and Man," <i>Recent Advances in Chemotherapy, Proceedings of the 14<sup>th</sup> International Congress of Chemotherapy, Kyoto</i> , pp. 2075-2076.				
	C3	Browne M.K. et al. (1976) "Taurolin, a New Chemotherapeutic Agent," <i>The Journal of Applied Bacteriology</i> , Vol. 41, pp. 363-368.				
	C4	Geistlich Catalog, "Taurolin, Triad antimicrobial chemotherapy" pp. 1-95.				
	C5	Gorman et al. (1987) "Reduced Adherence of Micro-Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent," <i>J. App. Bacteriol.</i> 62:315-320				
	C6	Hamik, A. et al. (1997) "Taurolidine Inhibits Tissue Factor Expression in Monocytes," <i>Abstract from the XVth Congress of the International Society on Thrombosis and Haemostasis</i> , Florence, June 6-12.				
	C7	Jacobi, C. et al. (1999) "New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat," <i>Digestive Surgery</i> , Vol. 16 (5), pp. 393-399.				
	C8	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.				
	C9	Jacobi, C. et al. (1999) "Influence of Different Gases and Intraperitoneal Instillation of Antiadherent of Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laproscopic Surgery in a Rat Model," <i>Surg. Endos.</i> 13:1021-25.				
	C10	Knight et al., (1983) "NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine," <i>J. Pharm. Sci.</i> 72:705-707				
	C11	Leaper et al. (1985) "Prevention of peritoneal adhesions after thermal injury using the formaldehyde carriers noxythidin and Taurolin," <i>Br. Soc. Gastroenterology</i> , page A901.				
	C12	McCourt, M. et al. (2000) "Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo," <i>Annals of Surgical Oncology</i> , Vol.. 7(9), pp. :685-691.				
	C13	Monson, J.R.T. et al. (1990) "Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial," <i>The British Journal of Surgery</i> , Vol. 77(6), pp. 711.				
	C14	Monson, J.R.T. et al. (1990) "Taurolidine as an anti-neoplastic agent: a previously undiscovered role?" <i>The British Journal of Surgery</i> , Vol. 77(12).				
	C15	Monson, J.R.T. et al., (1993) "Taurolidine inhibits tumor necrosis factor (TNF) toxicity new evidence of TNF and endotoxin synergy," <i>European Journal of Surgical Oncology</i> , 19:226-231.				
	C16	Reymond, M.A. et al. (2000) "Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator," <i>Surgical Endoscopy</i> , Vol. 14(1), pp. 51-55.				
	C17	Umpleby, H. et al. (1984) "The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma," <i>Annals of the Royal College of Surgeons of England</i> , 66:192-194.				
	C18	Volz J. et al. (2000) "Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model," <i>Cancer</i> , Vol. 89(2), pp. 262-266.				
	C19	Wicki, O. et al. (1983) "Solution for Surgical Lavage," <i>Langenbecks Archiv für Chirurgie</i> , p. 778, Abstract 276.				
ME	C20	International Search Report for PCT/US00/33103, mailed December 3, 2001.				

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Mina Haghighatian/	Date Considered	06/22/2006
--------------------	---------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/730,923
	<b>Filing Date</b>	December 6, 2000
	<b>First Named Inventor</b>	Paul Calabresi
	<b>Group Art Unit</b>	1619
	<b>Examiner Name</b>	M. Haghighatian
	<b>Attorney Docket Number</b>	23913-031(formerly 21486-031)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
MH	BH	WO	9403174	Pfirmann	2/17/94	X	
MH	BI	WO	9006138	Pfirmann	6/14/90	X	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
MH	CP	International Search Report.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office with the Information Disclosure Statement filed on August 22, 2001.

<b>Examiner Signature</b>	/Mina Haghighatian/	<b>Date Considered</b>	06/22/2006
-------------------------------	---------------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/730,923
	<b>Filing Date</b>	December 6, 2000
	<b>First Named Inventor</b>	Paul Calabresi
	<b>Group Art Unit</b>	1619
	<b>Examiner Name</b>	Unknown
	<b>Attorney Docket Number</b>	21486-031

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	3,423,408	01/21/69	Pfaffmann	260	243	
	AB	3,963,706	06/15/76	Pfaffmann	260	239.9	
	AC	4,096,241	06/20/78	Geistlich et al.	424	54	
	AD	4,107,305	08/15/78	Pfaffmann	424	246	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	BA	WO	91/13628	Pfaffmann et al.	09/19/91	X	
	BB	WO	92/00743	Monson	01/23/92	X	
	BC	WO	98/52572	Morrissey	11/26/98	X	
	BD	WO	99/06114	Pfaffmann	02/11/99	X	
	BE	WO	99/34805	Geistlich	07/15/99	X	
	BF	EPO	0253662	Geistlich	01/20/88	X	
	BG	EPO	1066830	Geistlich	01/10/01	X	

OTHER NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	CA	Blenkham et al. (1987) "The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics," Surg. Res. Commun., 2:149-155					
	CB	Browne M.K. et al. (1985) "Studies on the Antiendotoxin Properties of Taurolin in Animals and Man," Recent Advances in Chemotherapy, Proceedings of the 14 <sup>th</sup> International Congress of Chemotherapy, Kyoto, pp. 2075-2076.					
	CC	Browne M.K. et al. (1976) "Taurolin, a New Chemotherapeutic Agent," The Journal of Applied Bacteriology, Vol. 41, pp. 363-368.					

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

DUPLICATE

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/730,923
	<b>Filing Date</b>	December 6, 2000
	<b>First Named Inventor</b>	Paul Calabresi
	<b>Group Art Unit</b>	1619
	<b>Examiner Name</b>	Unknown
	<b>Attorney Docket Number</b>	21486-031

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AE	4,226,858	10/07/80	Pfirmann	424	195	
	AF	4,337,251	08/29/82	Pfirmann	424	246	
	AG	4,587,268	05/06/86	Geistlich et al.	514	774	
	AH	4,604,391	08/05/86	Pfirmann	514	222	
	AI	4,626,536	12/02/86	Pfirmann	514	222	
	AJ	4,772,468	09/20/88	Pfirmann	424	128	
	AK	5,210,083	05/11/93	Pfirmann	514	222.5	
	AL	5,573,771	11/12/96	Geistlich et al.	424	422	
	AM	5,593,665	01/14/97	Pfirmann et al.	424	85.1	
	AN	5,819,748	10/13/98	Pfirmann	128	898	
	AO	5,972,933	10/26/99	Pfirmann	514	222.5	
	AP	5,954,687	09/21/99	Baudino	604	48	
	AQ	5,976,822	11/2/99	Landrum et al.	435	23	
	AR	6,011,030	01/04/00	Pfirmann	514	222.2	
	AS	6,080,397	06/27/00	Pfirmann et al.	424	78.08	
	AT	6,117,868	09/12/00	Pfirmann	514	222.5	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CD	Geistlich Catalog, "Taurolin, Triad antimicrobial chemotherapy" pp. 1-95.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

DUPLICATE

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/730,923
	<b>Filing Date</b>	December 6, 2000
	<b>First Named Inventor</b>	Paul Calabresi
	<b>Group Art Unit</b>	1619
	<b>Examiner Name</b>	Unknown
	<b>Attorney Docket Number</b>	21486-031

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CE	Gormans et al. (1987) "Reduced Adherence of Micro-Organisms to Human Mucosal Epithelial Cells Following Treatment with Taurolin, a Novel Antimicrobial Agent," J. App. Bacteriol., 62:315-320
	CF	Hamik, A. et al. (1997) "Taurolidine Inhibits Tissue Factor Expression in Monocytes," <i>Abstract from the XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, June 6-12.</i>
	CG	Jacobi, C. et al. (1999) "New Therapeutic Strategies to Avoid Intra- and Extraperitoneal Metastases during Laparoscopy: Results of a Tumor Model in the Rat," <i>Digestive Surgery</i> , Vol. 16 (5), pp. 393-399
	CH	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.
	CI	Jacobi, C. et al. (1997) "Inhibition of Peritoneal Tumor Cell Growth and Implantation in Laparoscopic Surgery in a Rat Model," <i>The American Journal of Surgery</i> , Vol. 174 (3), pp. 359-363.
	CJ	Knight et al., (1983) "NMR Studies and GC Analysis of the Antibacterial Agent Taurolidine," J. Pharm. Sci. 72:705-707
	CK	Leaper et al. (1985) "Prevention of peritoneal adhesions after thermal injury using noxythidin and Taurolin" in a NEW CONCEPT IN ANTIMICROBIAL CHEMOTHERAPY FOR SURGICAL INFECTION, eds., WI Bruckner and RW Pfirman (Urban & Schwarzen: Munich, Vienna, Balt.), pages 115-119
	CL	McCourt, M. et al. (2000) "Taurolidine Inhibits Tumor Cell Growth In Vitro and In Vivo," <i>Annals of Surgical Oncology</i> , Vol. 7(9), pp. 685-691.
	CM	Monson, J.R.T. et al. (1990) "Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial," <i>The British Journal of Surgery</i> , Vol. 77(6), pp. 711.
	CN	Monson, J.R.T. et al. (1990) "Taurolidine as an anti-neoplastic agent: a previously undiscovered role?" <i>The British Journal of Surgery</i> , Vol. 77(12).
	CO	Monson, J.R.T. et al., (1993) "Taurolidine inhibits tumor necrosis factor (TNF) toxicity: new evidence of TNF and endotoxin synergy," <i>European Journal of Surgical Oncology</i> , 19:226-231.
	CP	Reymond, M.A. et al. (2000) "Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator," <i>Surgical Endoscopy</i> , Vol. 14(1), pp. 51-55.
	CQ	Umpleby, H. et al. (1984) "The efficacy of agents employed to prevent anastomotic recurrence in colorectal carcinoma," <i>Annals of the Royal College of Surgeons of England</i> , 66:192-194.
	CR	Volz J. et al. (2000) "Modulation of Tumor-Induced Lethality after Pneumoperitoneum in a Mouse Model," <i>Cancer</i> , Vol. 89(2), pp. 262-266.
	CS	Wicki, O. et al. (1983) "Solution for Surgical Lavage," <i>Langenbecks Archiv für Chirurgie</i> , p. 778, Abstract 276.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

DUPLICATE

TRA 1526316v1